Akebia Therapeutics Closes $4.1M in Series B
Akebia Therapeutics Inc., a pharmaceutical company focused on treatments for anemia, has drawn down a $4.1 million tranche of its previously announced Series B financing. Investors included Novartis Bioventures, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem Venture Fund.
9 January 2012•2 mins read
